Surveillance of cirrhosis for hepatocellular carcinoma: A cost-utility analysis

British Journal of Cancer

Volumn 98, Issue 7, 2008, Pages 1166-1175

  Thompson Coon, J ^a   Rogers, G ^a   Hewson, P ^b   Wright, D ^b   Anderson, R ^a   Jackson, S ^c   Ryder, S ^d   Cramp, M ^c   Stein, K ^a  

^a UNIVERSITY OF EXETER   (United Kingdom)

^b UNIVERSITY OF PLYMOUTH   (United Kingdom)

^c DERRIFORD HOSPITAL   (United Kingdom)

^d QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

Cirrhosis; Cost effectiveness; Cost utility; Hepatocellular carcinoma; Modelling studies; Surveillance

Indexed keywords

ALPHA FETOPROTEIN;

ALCOHOL LIVER DISEASE; ALGORITHM; ARTICLE; CANCER MORTALITY; CANCER SURGERY; COST UTILITY ANALYSIS; DISEASE SURVEILLANCE; HEPATITIS B; HEPATITIS C; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; PATHOGENESIS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SIMULATION; ULTRASOUND;

ALGORITHMS; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; FEMALE; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MODELS, BIOLOGICAL; MONITORING, PHYSIOLOGIC; ULTRASONOGRAPHY;

EID: 41649118950     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604301     Document Type: Article

References (49)

1. Arguedas MR, Chen VK, Eloubeidi MA, Fallon MB (2003) Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol 98: 679-690
2. Baron RL, Brancatelli G (2004) Computed tomographic imaging of hepatocellular carcinoma. Gastroenterology 127(5 Suppl 1): S133-S143
3. Bennett GL, Krinsky GA, Abitbol RJ, Kim SY, Theise ND, Teperman LW (2002) Sonographic detection of hepatocellular carcinoma and dysplastic nodules in cirrhosis: correlation of pretransplantation sonography and liver explant pathology in 200 patients. AJR Am J Roentgenol 179: 75-80
4. Brancatelli G, Baron RL, Peterson MS, Marsh W (2003) Helical CT screening for hepatocellular carcinoma in patients with cirrhosis: frequency and causes of false-positive interpretation. AJR Am J Roentgenol 180: 1007-1014
5. Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42: 1208-1236
6. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35: 421-430
7. Chong CA, Gulamhussein A, Heathcote EJ, Lilly L, Sherman M, Naglie G, Krahn M (2003) Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol 98: 630-638
8. Cottone M, Turri M, Caltagirone M, Maringhini A, Sciarrino E, Virdone R, Fusco G, Orlando A, Marino L, Pagliaro L (1988) Early detection of hepatocellular carcinoma associated with cirrhosis by ultrasound and alfafetoprotein: a prospective study. Hepatogastroenterology 35: 101-103
9. Cottone M, Turri M, Caltagirone M, Parisi P, Orlando A, Fiorentino G, Virdone R, Fusco G, Grasso R, Simonetti RG, Pagliaro L (1994) Screening for hepatocellular carcinoma in patients with Child's A cirrhosis: an 8-year prospective study by ultrasound and alphafetoprotein. J Hepatol 21: 1029-1034
10. De Masi S, Tosti ME, Mele A (2005) Screening for hepatocellular carcinoma. Dig Liver Dis 37: 260-268
11. Department of Health (DoH) (2005) Reference costs 2004. Department of Health: London. Available at http://www.dh.gov.uk/en/ Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4105545
12. Di Bisceglie AM (2005) Pretransplant treatments for hepatocellular carcinoma: do they improve outcomes? Liver Transpl 11: S10-S13
13. Ebara M, Ohto M, Shinagawa T, Sugiura N, Kimura K, Matsutani S, Morita M, Saisho H, Tsuchiya Y, Okuda K (1986) Natural history of minute hepatocellular carcinoma smaller than three centimeters complicating cirrhosis. A study in 22 patients. Gastroenterology 90: 289-298
14. Farinati F, Marino D, De Giorgio M, Baldan A, Cantarini M, Cursaro C, Rapaccini G, Del Poggio P, Di Nolfo MA, Benvegnu L, Zoli M, Borzio F, Bernardi M, Trevisani F (2006) Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol 101: 524-532
15. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, Nevens F, Solinas A, Mura D, Brouwer JT, Thomas H, Njapoum C, Casarin C, Bonetti P, Fuschi P, Basho J, Tocco A, Bhalla A, Galassini R, Noventa F, Schalm SW, Realdi G (1997) Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 112: 463-472
16. Fattovich G, Giustina G, Schalm SW, Hadziyannis S, Sanchez-Tapias J, Almasio P, Christensen E, Krogsgaard K, Degos F, Carneiro de MM (1995) Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology 21: 77-82
17. Fattovich G, Pantalena M, Zagni I, Realdi G, Schalm SW, Christensen E, European Concerted Action on Viral Hepatitis (EUROHEP) (2002) Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol 97: 2886-2895
18. Fattovich G, Stroffolini T, Zagni I, Donato F (2004) Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127: S35-S50
19. Fenwick E, Claxton K, Sculpher M (2001) Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 10: 779-787
20. Fenwick E, O'Brien B, Briggs A (2004) Cost-effectiveness acceptability curves - facts, fallacies and frequently asked questions. Health Econ 13: 405-415
21. Government Actuary's Department (2006) Interim life tables (2002- 2004) for England and Wales Available at http://www.gad.gov.uk/ demography_data/life tables/historical interim life tables.asp
22. Greten TF, Papendorf F, Bleck JS, Kirchhoff T, Wohlberedt T, Kubicka S, Klempnauer J, Galanski M, Manns MP (2005) Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. Br J Cancer 92: 1862-1868
23. HM Treasury (2003) Green Book: Appraisal and Evaluation in Central Government. TSO: London. Available at http://www.hm-treasury.gov.uk/ economic_data_and_tools/greenbook/data_greenbook_index.cfm
24. Izumi N, Asahina Y, Tsuchiya K, Kurosaki M, Nakanishi H, Kitamura T, Uchihara M, Miyake S (2007) Repeated radiofrequency ablation of the distant recurrence in the liver in patients with chronic hepatitis C virus infection achieving long-term survival. Hepatol Res 37(Suppl 2): S254-S263
25. Kim CK, Lim JH, Lee WJ (2001) Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver: accuracy of ultrasonography in transplant patients. J Ultrasound Med 20: 99-104
26. Lai CWY, Wardle M, Birkett V, Powell E, Thomas GAO (2002) Surveillance for hepatocellular carcinoma in cirrhosis: a national audit of the practice in the UK. Gut 50: A114
27. Lin OS, Keeffe EB, Sanders GD, Owens DK (2004) Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Aliment Pharmacol Ther 19: 1159-1172
28. Liu WC, Lim JH, Park CK, Kim MJ, Kim SH, Lee SJ, Lee WJ, Lim HK (2003) Poor sensitivity of sonography in detection of hepatocellular carcinoma in advanced liver cirrhosis: accuracy of pretransplantation sonography in 118 patients. Eur Radiol 13: 1693-1698
29. Llovet JM, Fuster J, Bruix J (1999) Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection vs transplantation. Hepatology 30: 1434-1440
30. Longworth L, Young T, Ratcliffe J, Bryan S, Buxton M (2001) Economic evaluation of the liver transplantation programme in England and Wales: an assessment of the costs of liver transplantation. Department of Health: London. Available at http://www.dh.gov.uk/en/Publicationsandstatistics/ Publications/PublicationsPolicyAndGuidance/DH_4005344
31. Oka H, Kurioka N, Kim K, Kanno T, Kuroki T, Mizoguchi Y, Kobayashi K (1990) Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis. Hepatology 12: 680-687
32. Patel D, Terrault NA, Yao FY, Bass NM, Ladabaum U (2005) Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 3: 75-84
33. Peng ZW, Zhang YJ, Chen MS, Liang HH, Li JQ, Zhang YQ, Lau WY (2008) Risk factors of survival after percutaneous radiofrequency ablation of hepatocellular carcinoma. Surg Oncol 17(1): 23-31 e-pub ahead of print
34. Ratcliffe J, Longworth L, Young T, Bryan S, Burroughs A, Buxton M (2002) Assessing health-related quality of life pre- and post-liver transplantation: a prospective multicenter study. Liver Transpl 8: 263-270
35. Roberts SE, Goldacre MJ, Yeates D (2005) Trends in mortality after hospital admission for liver cirrhosis in an English population from 1968 to 1999. Gut 54: 1615-1621
36. Rode A, Bancel B, Douek P, Chevallier M, Vilgrain V, Picaud G, Henry L, Berger F, Bizollon T, Gaudin JL, Ducerf C (2001) Small nodule detection in cirrhotic livers: evaluation with US, spiral CT, and MRI and correlation with pathologic examination of explanted liver. J Comput Assist Tomogr 25: 327-336
37. Ryder S (2003) Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut 52: iii1-iii8
38. Sherman M (2001) Alphafetoprotein: an obituary. J Hepatol 34: 603-605
39. Sheu JC, Sung JL, Chen DS, Yang PM, Lai MY, Lee CS, Hsu HC, Chuang CN, Yang PC, Wang TH (1985) Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology 89(2): 259-266
40. Sonnenberg FA, Beck JR (1993) Markov models in medical decision making: a practical guide. Med Decis Making 13: 322-338
41. Spreafico C, Marchiano A, Mazzaferro V, Frigerio LF, Regalia E, Lanocita R, Patelli G, Andreola S, Gaxbagnati F, Damascelli B (1997) Hepatocellular carcinoma in patients who undergo liver transplantation: sensitivity of CT with iodized oil. Radiology 203(2): 457-460
42. Taouli B, Goh JS, Lu Y, Qayyum A, Yeh BM, Merriman RB, Coakley FV (2005) Growth rate of hepatocellular carcinoma: evaluation with serial computed tomography or magnetic resonance imaging. J Comput Assist Tomogr 29: 425-429
43. Taouli B, Losada M, Holland A, Krinsky G (2004) Magnetic resonance imaging of hepatocellular carcinoma. Gastroenterology 127(Suppl 1): S144-S152
44. Trevisani F, De NS, Rapaccini G, Farinati F, Benvegnu L, Zoli M, Grazi GL, Del PP, Di N, Bernardi M, Italian Liver Cancer Group (2002) Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol 97: 734-744
45. Trevisani F, D'Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P, Domenicali M, De Notariis S, Roda E, Bernardi M (2001) Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 34: 570-575
46. Valls C, Cos M, Figueras J, Andia E, Ramos E, Sanchez A, Serrano T, Torras J (2004) Pretransplantation diagnosis and staging of hepatocellular carcinoma in patients with cirrhosis: value of dual-phase helical CT. Am J Roentgenol 182(4): 1011-1017
47. Wright M, Grieve R, Roberts J, Main J, Thomas HC (2006) Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol Assess 10: 1-113, iii
48. Zoli M, Magalotti D, Bianchi G, Gueli C, Marchesini G, Pisi E (1996) Efficacy of a surveillance program for early detection of hepatocellular carcinoma. Cancer 78: 977-985
49. Zytoon AA, Ishii H, Murakami K, El-Kholy MR, Furuse J, El-Dorry A, El-Malah A (2007) Recurrence-free survival after radiofrequency ablation of hepatocellular acrcinoma. A registry report of the impact of risk factors on outcome. Jpn J Clin Oncol 37: 658-672